Eyenovia, Inc. is a biopharmaceutical company revolutionizing the treatment of eye diseases such as glaucoma, mydriasis, and dry eyes through innovative research and development.

Eyenovia Inc, a biopharmaceutical company, faces significant volatility in the market despite its innovative approach and promising product pipeline for treating eye diseases.

Eyenovia Inc. has made significant strides in its financial performance and strategic initiatives, including merger talks with Betaliq and progress on its Optejet user-filled device.

Eyenovia Inc’s stock has experienced extreme volatility, with a 52-week high of $124.8 and a low of $0.85, raising concerns about the company’s long-term viability and financial health.